The history of the treatment of advanced NSCLC in ALK fusion-positive patients started in 2007 with Soda and his group’s discovery of the presence of the fusion protein ALK-EMLA4 in patients affected by NSCLC adenocarcinoma, who were mostly young patients and those who have never smoked [3]. This evidence concerns the gene ALK and adenocarcinoma.